{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:31:48Z","timestamp":1793291508656,"version":"4.5.0"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Since phosphorus is a component of hydroxyapatite, its prolonged deprivation affects bone mineralization. Fibroblast growth factor 23 (FGF23) is essential for maintaining phosphate homeostasis and is mainly produced by osteocytes. FGF23 increases the excretion of inorganic phosphate (Pi) and decreases the production of 1,25-dihydroxyvitamin D in the kidneys. Osteocytes are cells of osteoblastic lineage that have undergone terminal differentiation and become embedded in mineralized bone matrix. Osteocytes express <jats:italic>FGF23<\/jats:italic> and other multiple genes responsible for hereditary hypophosphatemic rickets, which include <jats:italic>phosphate-regulating gene homologous to endopeptidase on X chromosome<\/jats:italic> (<jats:italic>PHEX<\/jats:italic>), <jats:italic>dentin matrix protein 1<\/jats:italic> (<jats:italic>DMP1<\/jats:italic>), and <jats:italic>family with sequence similarity 20, member C<\/jats:italic> (<jats:italic>FAM20C<\/jats:italic>). Since inactivating mutations in <jats:italic>PHEX<\/jats:italic>, <jats:italic>DMP1<\/jats:italic>, and <jats:italic>FAM20C<\/jats:italic> boost the production of FGF23, these molecules might be considered as local negative regulators of FGF23. Mouse studies have suggested that enhanced FGF receptor (FGFR) signaling is involved in the overproduction of FGF23 in <jats:italic>PHEX<\/jats:italic>-deficient X-linked hypophosphatemic rickets (XLH) and <jats:italic>DMP1<\/jats:italic>-deficient autosomal recessive hypophosphatemic rickets type 1. Since FGFR is involved in the transduction of signals evoked by extracellular Pi, Pi sensing in osteocytes may be abnormal in these diseases. Serum levels of sclerostin, an inhibitor Wnt\/\u03b2-catenin signaling secreted by osteocytes, are increased in XLH patients, and mouse studies have suggested the potential of inhibiting sclerostin as a new therapeutic option for the disease. The elucidation of complex abnormalities in the osteocytes of FGF23-related hypophosphatemic diseases will provide a more detailed understanding of their pathogenesis and more effective treatments.<\/jats:p>","DOI":"10.3389\/fendo.2022.1005189","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T07:12:13Z","timestamp":1664435533000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Osteocytes and the pathogenesis of hypophosphatemic rickets"],"prefix":"10.3389","volume":"13","author":[{"given":"Miwa","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Michigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00022.2017","article-title":"Phosphate as a signaling molecule and its sensing mechanism","volume":"98","author":"Michigami","year":"2018","journal-title":"Physiol Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00180","article-title":"Roles of phosphate in skeleton","volume":"10","author":"Michigami","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200419081","article-title":"Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin d metabolism","volume":"113","author":"Shimada","year":"2004","journal-title":"J Clin Invest."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/JME-20-0089","article-title":"FGF23-related hypophosphatemic rickets\/osteomalacia: diagnosis and new treatment","volume":"66","author":"Fukumoto","year":"2021","journal-title":"J Mol Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1152\/physrev.00043.2020","article-title":"The osteocyte as a signaling cell","volume":"102","author":"Delgado-Calle","year":"2022","journal-title":"Physiol Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am J Hum Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52 kb deletion downstream of the SOST gene in patients with van buchem disease","volume":"39","author":"Balemans","year":"2002","journal-title":"J Med Genet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093840","article-title":"Dysregulated gene expression in the primary osteoblasts and osteocytes isolated from hypophosphatemic hyp mice","volume":"9","author":"Miyagawa","year":"2014","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-013-1418-6","article-title":"The SLC34 family of sodium-dependent phosphate transporters","volume":"466","author":"Wagner","year":"2014","journal-title":"Pflugers Arch"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1402218111","article-title":"Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis","volume":"111","author":"Tagliabracci","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M602469200","article-title":"Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. secretion of fibroblast growth factor 23 requires O-glycosylation","volume":"281","author":"Kato","year":"2006","journal-title":"J Biol Chem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021105","article-title":"Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia","volume":"87","author":"Yamazaki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature05315","article-title":"Klotho converts canonical FGF receptor into a specific receptor for FGF23","volume":"444","author":"Urakawa","year":"2006","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C500457200","article-title":"Regulation of fibroblast growth factor-23 signaling by klotho","volume":"281","author":"Kurosu","year":"2006","journal-title":"J Biol Chem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"116087","DOI":"10.1016\/j.bone.2021.116087","article-title":"The wnt pathway: An important control mechanism in bone\u2019s response to mechanical loading","volume":"153","author":"Choi","year":"2021","journal-title":"Bone"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J Biol Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2019.10.174","article-title":"Mechanotransduction via the Piezo1-akt pathway underlies sost suppression in osteocytes","volume":"521","author":"Sasaki","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070804","article-title":"Control of the SOST bone enhancer by PTH using MEF2 transcription factors","volume":"22","author":"Leupin","year":"2007","journal-title":"J Bone Miner Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"13176","DOI":"10.1038\/ncomms13176","article-title":"SIKs control osteocyte responses to parathyroid hormone","volume":"7","author":"Wein","year":"2016","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-021-06095-y","article-title":"A systematic review and meta-analysis of efficacy and safety of romosozumab in postmenopausal osteoporosis","volume":"33","author":"Singh","year":"2022","journal-title":"Osteoporos Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: Results of a randomized phase 2a trial","volume":"32","author":"Glorieux","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2452","article-title":"Evidence for osteocyte regulation of bone homeostasis through RANKL expression","volume":"17","author":"Nakashima","year":"2011","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2448","article-title":"Matrix-embedded cells control osteoclast formation","volume":"17","author":"Xiong","year":"2011","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138189","article-title":"Osteocytes, not osteoblasts or lining cells, are the main source of the RANKL required for osteoclast formation in remodeling bone","volume":"10","author":"Xiong","year":"2015","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138815","article-title":"Osteocyte RANKL is required for cortical bone loss with age and is induced by senescence","volume":"5","author":"Kim","year":"2020","journal-title":"JCI Insight"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23","volume":"26","year":"2000","journal-title":"Nat Genet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00064.x","article-title":"Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23","volume":"60","author":"White","year":"2001","journal-title":"Kidney Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070107","article-title":"FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets","volume":"22","author":"Imel","year":"2007","journal-title":"J Bone Miner Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1239","article-title":"Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans","volume":"96","author":"Imel","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1110905108","article-title":"Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice","volume":"108","author":"Farrow","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/ng1095-130","article-title":"A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets","volume":"11","author":"Francis","year":"1995","journal-title":"HYP Consortium. Nat Genet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/BF02405074","article-title":"Relation between hypomineralized periosteocytic lesions and bone mineralization in vitamin d-resistant rickets","volume":"35","author":"Marie","year":"1983","journal-title":"Calcif Tissue Int"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119276","article-title":"Pex\/PEX tissue distribution and evidence for a deletion in the 3\u2019 region of the pex gene in X-linked hypophosphatemic mice","volume":"99","author":"Beck","year":"1997","journal-title":"J Clin Invest."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00008.2006","article-title":"Pathogenic role of Fgf23 in hyp mice","volume":"291","author":"Liu","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32702","article-title":"Aberrant phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia","volume":"118","author":"Yuan","year":"2008","journal-title":"J Clin Invest."},{"key":"B40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1523-1755.2000.00807.x","article-title":"PHEX gene and hypophosphatemia","volume":"57","author":"Drezner","year":"2000","journal-title":"Kidney Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.699767","article-title":"Genotype and phenotype analysis in X-linked hypophosphatemia","volume":"9","author":"Park","year":"2021","journal-title":"Front Pediatr"},{"key":"B42","doi-asserted-by":"publisher","first-page":"116135","DOI":"10.1016\/j.bone.2021.116135","article-title":"Genotype-phenotype analysis, and assessment of the importance of the zinc-binding site in PHEX in Japanese patients with X-linked hypophosphatemic rickets using 3D structure modeling","volume":"153","author":"Ishihara","year":"2021","journal-title":"Bone"},{"key":"B43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.bone.2004.09.015","article-title":"Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP)","volume":"36","author":"Rowe","year":"2005","journal-title":"Bone"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080601","article-title":"MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM","volume":"23","author":"Addison","year":"2008","journal-title":"J Bone Miner Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1677\/joe.1.05989","article-title":"Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets","volume":"183","author":"Bresler","year":"2004","journal-title":"J Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1359\/jbmr.090832","article-title":"Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage","volume":"25","author":"Addison","year":"2010","journal-title":"J Bone Miner Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1766","article-title":"Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in hyp mouse bone, the murine model of X-linked hypophosphatemia","volume":"28","author":"Barros","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4101","article-title":"Genetic ablation of osteopontin in osteomalacic hyp mice partially rescues the deficient mineralization without correcting hypophosphatemia","volume":"35","author":"Hoac","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1096\/fj.10-177816","article-title":"Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling","volume":"25","author":"Martin","year":"2011","journal-title":"FASEB J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104154","article-title":"Osteocyte-specific deletion of Fgfr1 suppresses FGF23","volume":"9","author":"Xiao","year":"2014","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.22842","article-title":"Both FGF23 and extracellular phosphate activate Raf\/MEK\/ERK pathway via FGF receptors in HEK293 cells","volume":"111","author":"Yamazaki","year":"2010","journal-title":"J Cell Biochem"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.08.006","article-title":"Signaling of extracellular inorganic phosphate up-regulates cyclin D1 expression in proliferating chondrocytes via the Na+\/Pi cotransporter pit-1 and Raf\/MEK\/ERK pathway","volume":"47","author":"Kimata","year":"2010","journal-title":"Bone"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.25742","article-title":"Extracellular phosphate induces the expression of dentin matrix protein 1 through the FGF receptor in osteoblasts","volume":"118","author":"Nishino","year":"2017","journal-title":"J Cell Biochem"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1815166116","article-title":"Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation","volume":"116","author":"Takashi","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/ng1868","article-title":"DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis","volume":"38","author":"Lorenz-Depiereux","year":"2006","journal-title":"Nat Genet"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/ng1905","article-title":"Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism","volume":"38","author":"Feng","year":"2006","journal-title":"Nat Genet"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3683","article-title":"DMP1 ablation in the rabbit results in mineralization defects and abnormalities in haversian Canal\/Osteon microarchitecture","volume":"34","author":"Liu","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2010.01.006","article-title":"Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets","volume":"86","author":"Lorenz-Depiereux","year":"2010","journal-title":"Am J Hum Genet"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2010.01.010","article-title":"Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene","volume":"86","author":"Levy-Litan","year":"2010","journal-title":"Am J Hum Genet"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/humu.24391","article-title":"Mutation update: Variants of the ENPP1 gene in pathologic calcification, hypophosphatemic rickets, and cutaneous hypopigmentation with punctate keratoderma","volume":"43","author":"Ralph","year":"2022","journal-title":"Hum Mutat"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/ng1221","article-title":"Mutations in ENPP1 are associated with \u2018idiopathic\u2019 infantile arterial calcification","volume":"34","author":"Rutsch","year":"2003","journal-title":"Nat Genet"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2012.07.014","article-title":"New insights into NPP1 function: lessons from clinical and animal studies","volume":"51","author":"Mackenzie","year":"2012","journal-title":"Bone"},{"key":"B63","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11914-016-0309-0","article-title":"Hypophosphatasia","volume":"14","author":"Linglart","year":"2016","journal-title":"Curr Osteoporos Rep"},{"key":"B64","doi-asserted-by":"publisher","first-page":"115656","DOI":"10.1016\/j.bone.2020.115656","article-title":"Genetic pathways disrupted by ENPP1 deficiency provide insight into mechanisms of osteoporosis, osteomalacia, and paradoxical mineralization","volume":"142","author":"Maulding","year":"2021","journal-title":"Bone"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1850","article-title":"Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23-related hypophosphatemia, dental anomalies, and ectopic calcification","volume":"28","author":"Rafaelsen","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.bone.2014.06.026","article-title":"Hypophosphatemic osteomalacia and bone sclerosis caused by a novel homozygous mutation of the FAM20C gene in an elderly man with a mild variant of raine syndrome","volume":"67","author":"Takeyari","year":"2014","journal-title":"Bone"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1126\/science.1217817","article-title":"Secreted kinase phosphorylates extracellular proteins that regulate biomineralization","volume":"336","author":"Tagliabracci","year":"2012","journal-title":"Science"},{"key":"B68","doi-asserted-by":"publisher","first-page":"8039","DOI":"10.3390\/ijms22158039","article-title":"FAM20C overview: Classic and novel targets, pathogenic variants and raine syndrome phenotypes","volume":"22","author":"Palma-Lara","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002708","article-title":"Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice","volume":"8","author":"Wang","year":"2012","journal-title":"PloS Genet"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26200","article-title":"FAM20C regulates osteoblast behaviors and intracellular signaling pathways in a cell-autonomous manner","volume":"233","author":"Liu","year":"2018","journal-title":"J Cell Physiol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3109\/03008207.2014.923414","article-title":"Overexpression of Dmp1 fails to rescue the bone and dentin defects in Fam20C knockout mice","volume":"55","author":"Wang","year":"2014","journal-title":"Connect Tissue Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030036","article-title":"Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets","volume":"88","author":"Makitie","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: Week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3852","article-title":"Circulating sclerostin in children and young adults with heritable bone disorders","volume":"99","author":"Palomo","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-019-00526-z","article-title":"Elevated bone remodeling markers of CTX and P1NP in addition to sclerostin in patients with X-linked hypophosphatemia: A cross-sectional controlled study","volume":"104","author":"Hansen","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"B79","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s00223-021-00823-6","article-title":"Sclerostin directly stimulates osteocyte synthesis of fibroblast growth factor-23","volume":"109","author":"Ito","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"B80","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/jbmr.3923","article-title":"Sclerostin antibody treatment increases bone mass and normalizes circulating phosphate levels in growing hyp mice","volume":"35","author":"Carpenter","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"116201","DOI":"10.1016\/j.bone.2021.116201","article-title":"Sclerostin antibody improves phosphate metabolism hormones, bone formation rates, and bone mass in adult hyp mice","volume":"154","author":"Carpenter","year":"2022","journal-title":"Bone"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1005189\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T07:12:16Z","timestamp":1664435536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1005189\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":81,"alternative-id":["10.3389\/fendo.2022.1005189"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1005189","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"article-number":"1005189"}}